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Background: Survival in amyotrophic lateral sclerosis varies considerably. About one third of the patients die within
12 months after first diagnosis. The early recognition of fast progression is essential for patients and neurologists
to weigh up invasive therapeutic interventions. In a prospective, population-based cohort of ALS patients in
Rhineland-Palatinate, Germany, we identified significant prognostic factors at time of diagnosis that allow prediction
of early death within first 12 months.
Methods: Incident cases, diagnosed between October 2009 and September 2012 were enrolled and followed up
at regular intervals of 3 to 6 months. Univariate analysis utilized the Log-Rank Test to identify association between
candidate demographic and disease variables and one-year mortality. In a second step we investigated a multiple
logistic regression model for the optimal prediction of one-year mortality rate.
Results: In the cohort of 176 ALS patients (mean age 66.2 years; follow-up 100%) one-year mortality rate from
diagnosis was 34.1%. Multivariate analysis revealed that age over 75 years, interval between symptom onset and
diagnosis below 7 months, decline of body weight before diagnosis exceeding 2 BMI units and Functional Rating
Score below 31 points were independent factors predicting early death.
Conclusions: Probability of early death within 12 months from diagnosis is predicted by advanced age, short
interval between symptom onset and first diagnosis, rapid decline of body weight before diagnosis and advanced
functional impairment.
Trial registration: ClinicalTrials.gov (NCT01955369, registered September 28, 2013)
Keywords: Amyotrophic lateral sclerosis, Mortality rate, Prognostic factors, Population registerBackground
Amyotrophic lateral sclerosis (ALS) is a severe neurode-
generative disease with a progressive decline of upper and
lower motor neurons leading to disability and death. Sur-
vival in ALS is highly variable, with a wide range from a
few months to many years. Population-based prospective
registries report one-year mortality rates after diagnosis
ranging from 22% [1,2] to 34% [3]. Early identification of a
potentially malignant variant of ALS would be essential
for patients to take vital decisions, and might help patients* Correspondence: wolfj@klilu.de
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unless otherwise stated.in cooperation with their neurologists to decide in favour
or against possibly burdensome invasive therapeutic in-
terventions, like percutaneous endoscopic gastrostomy or
mechanical ventilation.
Previous population-based ALS registries identified
different prognostic factors of overall survival including
demographic factors (age at onset, gender), clinical factors
(e.g. type of onset, rate of disease progression), and factors
related to nutrition or respiration [4].
Our study is based on a prospective, population-based
cohort of ALS patients. The aim of our paper is to identify
prognostic factors at time of diagnosis related to fast dis-
ease progression and early death within 12 months after
first diagnosis.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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In 2009 a prospective and population-based ALS registry
was established in Rhineland-Palatinate, a state in the
south-west of Germany with 4 million inhabitants (cen-
sus data 2011: n = 3989800, 1950420 men, and 2039380
women) [5]. Newly diagnosed ALS patients in the period
October 2009 to September 2012 were enrolled and
followed-up at regular intervals of 3 to 6 months. Eligible
patients had a minimum age of 18 years. We used multiple
overlapping sources of information to ensure completeness
of case ascertainment. The establishment of the ALS regis-
try Rhineland-Palatinate has recently been described [6].
The registry has been approved by the data protection
commissioner and by the local ethics committee of
Rhineland-Palatinate (registration-number 837.253.09).
It has been registered in the publicly accessible trial
register ClinicalTrials.gov (NCT01955369). According to
legal requirements, patients could be registered at the
data holding centre (Department of Neurology, Klinikum
Ludwigshafen), including personal data, if written infor-
med consent signed by patient or the legal representative
was available. In the absence of written informed con-
sent, a basic data set (demographic and phenotypic data)
was generated with the use of a pseudonymisation code,
a procedure to avoid double registration.
We used the revised El Escorial criteria (EEC) [7] to
classify cases into four categories of disease likelihood:
possible ALS, probable ALS with laboratory confirm-
ation, probable respectively definite ALS, depending on
the presence of upper and lower motor neuron involve-
ment in defined body regions. Patients with a pure lower or
a pure upper motor neuron disease were excluded. Func-
tional impairment was assessed by the ALS Functional
Rating Scale (FRS) in the initially published version [8].
Minimum follow-up period for this paper was 18 months.
All times to death have been observed, and thus there was
no censoring of observations. To determine the causes of
death we used information of attending physicians, neurol-
ogists and family members as well as data of death certifi-
cates from local health authorities.
Statistical analysis
One-year mortality rate was tested for independence
univariately with all candidate factors for survival predic-
tion using the Log-Rank Test (LRT). Continuous variables
were subdivided into categories by one or more cut-points
with commonly accepted values or, if not applicable, with
groups of approximately equal numbers. This procedure
was applied to age (<65, 66–75, >75 years), gender (male,
female), site of onset (bulbar, spinal), site of spinal onset
(upper limbs, lower limbs, upper and lower limbs, trunk),
delay between symptom onset and diagnosis (DOD, 0–6,
7–12, 13–24 months, ≥25 months), body-mass-index
(BMI) (<25, ≥25 kg/m2), difference between BMI atdiagnosis and six months before according to patients’
statement (Diff-BMI, <1, 1- < 2, ≥2), EEC (possible, prob-
able with laboratory confirmation, probable, definite),
FRS (>32, ≤32, and subdivided into quintiles: <27, 27–
30, 31–33, 34–36, 37–40), forced vital capacity (FVC,
<80, ≥80%), creatine kinase (CK, <150, ≥150 U/l), pCO2
(<42, ≥42 mmHg), previous alcohol consumption status
(no, yes), previous smoking status (no, yes), and social life
(single person, living in a partnership). Time was mea-
sured in months from date of diagnosis to death or to
tracheostomy, and categorized to a binary survival variable
(1 = death within 12 months; 0 = survival > 12 months).
We predicted 1-year death rate by a multiple logistic
regression model from those demographic and disease
variables at time of diagnosis that were identified as sta-
tistically significant. Starting with the maximum number
of predictors, a stepwise selection procedure was used to
eliminate the non-significant variables from the full
model. Model fit was described by LRT for the global
Null hypothesis (all regression coefficients β =0). R2 is the
coefficient of determination describing the percentage of
total variability being explained by the model.
The relationship between mortality rate one year after
diagnosis and FRS at diagnosis is visualized by a bubble
plot, with the estimated logistic regression function pre-
dicting% mortality rate from FRS. The area of the bubbles
is proportional to the number of observations.
P-values ≤0.05 were considered significant. All data were
analysed using SAS 9.3 software (SAS Institute, North
Carolina), PROC LIFETEST being used for the Log-Rank
Test, and PROC LOGISTIC for the logistic model predict-
ing 12-month mortality rate.
Results
During the three year surveillance period 200 incident
ALS patients (106 males, 94 females) were enrolled. 24 pa-
tients (10 males, 14 females) were lost during early follow-
up (17 patients after date of diagnosis, 7 patients after first
follow-up), and therefore excluded. Demographic data of
the excluded patients didn’t differ from those 176 patients,
which have been tracked for status 12 months after first
diagnosis.
Mean age at diagnosis was 66.2 years (SD 10.3, range 23–
85, median 68), in men 65.1 years (range 23–85, median
67), and in women 67.4 years (range 30–85, median 70).
Mean DOD was 12.5 months (SD 12.8, median 9). One
year mortality rate from diagnosis was 34.1% (N= 60). The
causes of death regarding patients who had died within
12 months from first diagnosis encompassed respiratory
failure due to weakness of breathing muscle pump (n = 34;
56.7%) and due to pneumonia (n = 7; 11.7%), death from
cachexia and marasmus (n = 6; 10%), and cardiovascular
causes of death including sudden death (n = 4; 6.7%). In 9
patients the causes of death could not be determined (15%).
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Table 1 shows the results of categorical analysis of tested
variables potentially related to rapid decline and early
mortality in ALS. Due to complete tracking over the first
year after ALS diagnosis all survival times are observed,
and none is censored.
In univariate analysis death within 12 months was
significantly influenced by several variables. Age over
75 years, short DOD (≤6 months), Diff-BMI ≥ 2, low FRS
(<32), low FVC (<80%), pCO2 over >42 mmHg and level
of diagnostic certainty according to EEC being probable
or definite were associated with a prognosis of increased
probability of death one year after diagnosis. A slight but
not significant trend was observed for previous con-
sumption of alcohol with lower mortality rate (p = 0.08).
The strongest association between 12-month mortality
and candidate predictors was found with FRS (maximum-
scaled coefficient of determination R2 = 0.368) (Figure 1).
The final multiple logistic model retained four fac-
tors with significant influence on 12-month mortality
rate: advanced age at diagnosis (with 3 discrete age cat-
egories), and the predictors DOD, Diff-BMI and FRS
(Table 2).
Increased mortality rate was predicted by age: the odds
ratio (OR) of one-year mortality rate was 6.2 (95% CI:
1.5 – 25; p = 0.01) for patients over 75 years compared
to those diagnosed at ≤65 years. Increased mortality rate
was also linked to short DOD. There was a non-signifi-
cantly reduced OR of 0.42 for DOD 7 – 12 months resp.
0.45 for DOD 13 – 24 months, compared to DOD up to
6 months. Such patients with DOD over 24 months
showed a significantly reduced OR of 0.05 (95% CI:
0.005 – 0.48; p = 0.009). These are the best candidates
for longer term survival. Loss of at least 2 BMI units
during the 6 months preceding diagnosis was linked
to a significant increase of OR (2.8, 95% CI: 1.04 – 7.7;
p = 0.04), compared to loss of weight less than one BMI
unit. Low FRS was linked to high probability of one-year
mortality, as visualized by Figure 1. In the multiple logistic
model the separation of FRS into quintiles (reference: quin-
tile 1: 37 – 40) showed a strictly increasing OR by quintiles
2 to 5 with significantly increased OR for quintile 4 (FRS
27 – 30; OR 12.9, 95% CI: 2.8 – 60; p = 0.001) and quintile
5 (FRS ≤26; OR 33.8, 95% CI: 6.7 – 170; p < 0.0001).
Discussion
In contrast to previous studies which analysed prog-
nostic factors with regard to overall survival [2-4,9] we
focussed our analysis on variables predicting one-year
mortality after first diagnosis in a population-based
prospective cohort of 176 ALS patients in Rhineland-
Palatinate, Germany.
In this cohort one-year mortality rate was 34%, which
is in the upper range of results of previous population-based registries [1-3]. The categorized variables age over
75 years, interval between symptom onset and diagnosis
up to 6 months, decline of body weight of 2 or more
BMI units during 6 months preceding diagnosis and
progressed functional impairment (FRS ≤30) were signi-
ficant and independent predictors of mortality rate one
year after diagnosis. The FRS at time of first diagnosis
showed the strongest prognostic value for risk of death,
explaining about 37% of the total variance, while the
four-factor model explains about 54%.
In concordance with findings of other population-based
studies the age at diagnosis was a strong prognostic
variable [2,3,10]. Elder patients over 75 years showed
distinctly elevated one-year mortality by a factor of
about 6 compared to younger patients up to 65 years. In
comparison to the local population over 75 years with
one-year mortality risk of 7.8% for men and 4.6% for
women [5] there was a more than ten-fold elevated
one-year mortality risk both for male and female ALS
patients over 75 years (81.1% resp. 66.7%).
Several authors postulated that patients with an ag-
gressive disease form sought medical help earlier and
diagnostic process was easier and therefore faster
[2,3,10-12]. This fact might also explain the shortened
latency between onset and diagnosis and the linkage to
early death in our study.
Nutritional status deteriorates during the course of
disease, and a detrimental nutritional status at diagnosis
seems to be associated with increased mortality [13]. In
our study crude BMI at diagnosis was no marker of an
elevated risk of death, but a marked decrease of BMI
within a 6 months interval preceding diagnosis (> = 2
BMI units) predicted a fatal disease progression. Corre-
sponding to a previous study finding [14], we conclude
that weight loss at diagnosis but not body weight or BMI
was another relevant prognostic factor. However the
information of BMI 6 months prior to diagnosis was
based on patients’ statements, and therefore susceptible
to inaccuracy.
Additionally, we found that a low FRS score at diagno-
sis indicating an advanced functional impairment was a
clear marker of increased probability of death during
first year after diagnosis (Figure 1). Similar results both
for the ALSFRS [15,16], which we used, and for the
revised version (ALSFRS-R) have been previously identi-
fied in hospital based studies [17,18].
The El Escorial criteria are a structured tool to define
the diagnostic certainty of ALS in individual patients.
Although mainly intended for use in research settings
[4], several studies could demonstrate that EEC are a
valid prognostic marker [2,10], and that the level of def-
inite ALS at diagnosis had a worse prognosis than other
EEC levels. In contrast, Zoccolella et al. [9] found no
clear correlation between EEC and survival. In our study
Table 1 Univariate analysis of potential prognostic factors associated with mortality one year after first diagnosis (N = 176)
Parameters at FD N Category Total Death during 12 months from FD Log-rank test
ob-served mis-sing n = 60 % X2 (DF) p(X2)
Age 176 0 ≤ 65 69 18 26% 24.13 (2) < 0.0001
66-75 84 25 30%
> 75 23 17 74%
Gender 176 0 male 96 31 32% 0.29 (1) 0.59
female 80 29 36%
Site of onset 176 0 bulbar 62 25 40% 1.71 (1) 0.19
spinal 114 35 31%
Site of spinal onset 114 0 upper limbs 39 10 26% 2.58 (4) 0.64
lower limbs 60 20 33%
upper + lower limbs 8 3 38%
trunk 7 2 29%
DOD [months] 176 0 0 - 6 60 27 45% 9.41 (3) 0.024
07-12 61 17 28%
13-24 37 15 41%
≥ 25 18 1 6%
BMI [kg/m2] 173 3 < 25 92 34 37% 0.97 (1) 0.33
≥ 25 81 24 30%
Diff-BMI [kg/m2] 173 3 < 1 87 14 16% 33.14 (2) < 0.0001
1 - < 2 31 11 35%
≥ 2 55 33 60%
EEC 176 0 possible 31 6 19% 16.21 (3) 0.001
probable (lab. conf.) 54 12 22%
probable 63 26 41%
definite 28 16 57%
FRS 173 3 < 32 72 44 61% 46.92 (1) < 0.0001
≥ 32 101 14 14%
FVC [%] 153 23 < 80 31 19 61% 28.61 (1) < 0.0001
≥ 80 122 27 22%
PCO2 [mm Hg] 134 42 < 42 112 33 29% 15.97 (1) < 0.0001
≥ 42 22 14 64%
CK [U/l] 153 23 < 150 73 27 37% 1.29 (1) 0.26
≥ 150 80 24 30%
Pre-alcohol cons. status 149 27 no 62 26 42% 2.99 (1) 0.084
yes 87 19 22%
Pre-smoking status 151 25 no 85 23 27% 0.69 (1) 0.41
yes 66 23 35%
social life 153 23 living in a partnership 109 28 26% 1.59 (1) 0.21
single person 44 19 43%
Abbreviations DOD delay between onset and diagnosis FD first diagnosis
BMI body mass index FRS functional rating scale
Diff-BMI difference between BMI at diagnosis and
six months before
FVC forced vital capacity
PCO2 carbondioxide pressure in blood
EEC revised El Escorial criteria CK creatinine kinase
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Figure 1 Mortality rate one year after first diagnosis (FD) of ALS by FRS at FD. Observed rates: bubble area proportional to number of
observations; black dots: logistic function estimate.
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variate analysis we could not confirm the finding that
criteria defining higher levels of certainty (definite, prob-
able ALS) and therefore indicating a more widespread
clinical involvement pointed to a worse prognosis within
12 months from diagnosis. It might be possible that only
analyses of overall survival with long observation periodTable 2 Multiple logistic regression model predicting the one










1- < 2 1 0.227
> = 2 1 1.038
FRS Quintile 1: 37-40 0.000
Quintile 2: 34-36 1 0.588
Quintile 3: 31-33 1 0.953
Quintile 4: 27-30 1 2.556
Quintile 5: 00-26 1 3.520
Testing the global null hypothesis: BETA= 0
Likelihood ratio test 11
R2 0.543
Abbreviations: OR odds ratio, CI confidence interval, R2 coefficient of determination.reveal prognostic effects of EEC. This explanation might
also be valid for factors reflecting respiratory status at
diagnosis (FVC, pCO2) or site of onset. Respiratory vari-
ables had no prognostic relevance concerning one-year
mortality in our study. However, with regard to the whole
course of the disease, FVC < 75% was associated with a
poor prognosis in a clinic-based cohort of 1034 patients-year mortality rate in ALS patients (N = 176)
Standard error (b) Wald X2 p OR (95% CI)
0.702 10.93 0.001
Reference 1
0.473 0.07 0.80 1.13 (0.45 - 2.85)
0.709 6.60 0.01 6.2 (1.5 - 25)
Reference 1
0.523 2.74 0.10 0.42 (0.15 - 1.17)
0.594 1.85 0.17 0.45 (0.14 - 1.4)
1.151 6.78 0.01 0.050 (0.005 - 0.48)
Reference 1
0.591 0.15 0.70 1.26 (0.39 - 4.0)
0.512 4.11 0.04 2.8 (1.04 - 7.7)
Reference 1
0.796 0.55 0.46 1.8 (0.38 - 8.6)
0.795 1.47 0.23 2.6 (0.55 - 12)
0.786 10.57 0.001 12.9 (2.8- 60)
0.823 18.28 <.0001 33.8 (6.7 - 170)
87.67 <.0001
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within 12 months from first diagnosis, whereas other
population-based studies found worse prognosis in bulbar
onset ALS [3,9,10].
The major weaknesses of our study material are the lim-
ited number of patients in the registry, and the resulting
lack of statistical power to detect possibly important fac-
tors of minor strength.
Despite of the limited number of patients this study
has several strengths. The population-based prospective
approach is representative of the overall ALS population.
Thus data on survival as well as the analysis of prog-
nostic factors are based on all ALS cases and are least
likely to be affected by bias [1]. Here we captured a
multitude of possibly relevant variables and restricted
our point of view to early mortality within 12 months
from diagnosis.Conclusions
Our results confirm that there are several valid predictors
of one-year mortality rate in ALS even at time of diag-
nosis: age over 75 years, short interval between symptom
onset and diagnosis (≤6 months), rapid decline of body
weight before diagnosis (≥2 BMI units within 6 months)
and advanced functional impairment (FRS ≤ 30 points).
These predictor variables of one-year mortality are easy to
assess and have the potential to support neurologists and
patients in their further therapeutic decisions.
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